When challenged against primary mammary tumors, transgenic Omomyc dramatically reduced tumor expansion by reducing cell proliferation and enhancing apoptosis, in line with what had been shown in the MMTV-Wnt1 mouse model of breast cancer (81), and with previous reports showing that indirect inhibition of MYC is extremely effective in the treatment of TNBC models (82). The gene discussed is MYC; the disease is breast carcinoma.